Samsung Biologics Co.,Ltd. (KRX: 207940)

Market Cap	66.90T
Revenue (ttm)	4.36T
Net Income (ttm)	1.05T
Shares Out	71.17M
EPS (ttm)	14,787.79
PE Ratio	63.57
Forward PE	61.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,072
Open	934,000
Previous Close	934,000
Day's Range	932,000 - 951,000
52-Week Range	721,000 - 1,113
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 24, 2025

About Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd. engages in the contract development and manufacturing organization (CDMO) business for biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates in two segments, CDMO, and Biopharmaceutical Development and Commercialization. Its development services include discovery, cell line development, process development, and clinical manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality ass...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,744
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2023, Samsung Biologics Co.,Ltd.'s revenue was 3.69 trillion, an increase of 23.10% compared to the previous year's 3.00 trillion. Earnings were 857.69 billion, an increase of 7.47%.